Plasmodium falciparum and Plasmodium yoelii: Effect of the iron chelation prodrug dexrazoxane on in vitro cultures

Experimental Parasitology

Volumn 91, Issue 2, 1999, Pages 105-114

  Loyevsky, Mark ^a   Sacci Jr , John B ^b,c   Boehme, Patricia ^a   Weglicki, William ^a   John, Christy ^a   Gordeuk, Victor R ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b NAVAL MEDICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Dexrazoxane (ICRF 187); Dexrazoxane (ICRF 187) (+) 1,2 bis(3,5 dioxopiperazinyl 1 yl)propane ; ICRF 159, (+, ) 1,2 bis(3,5 dioxopiperazinyl 1 yl)propane ; ICRF 198, two ring open product of dexrazoxane; Iron chelation; Malari; P falciparum; P yoelii

Indexed keywords

DEFEROXAMINE; DOXORUBICIN; PRODRUG; RAZOXANE;

ANTIMALARIAL ACTIVITY; ARTICLE; CARDIOTOXICITY; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG STRUCTURE; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; IRON CHELATION; MICROBIAL GROWTH; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII; PRIORITY JOURNAL;

PLASMODIUM FALCIPARUM; PLASMODIUM YOELII; PROTOZOA; STAPHYLOCOCCUS PHAGE 187;

EID: 0032788366     PISSN: 00144894     EISSN: None     Source Type: Journal    
DOI: 10.1006/expr.1998.4371     Document Type: Article

References (30)

1. Breuer W., Epsztejn S., Millgram P., Cabantchik Z. I. Transport of iron and other transition metals into cells as revealed by a fluorescent probe. American Journal of Physiology. 268:1995;C1354-C1361.
2. Brittenham G. M. Iron chelating agents. Current Therapy in Hematology Oncology. 1988;Mosby, St. Louis. p. 149-153.
3. Brooks P. B., Jones E. A., Kim B.-D., Sander E. G. Bovine liver dihydropyrimidine amidohydrolase: purification, properties, and characterization as a zinc metalloenzyme. Archives of Biochemistry and Biophysics. 226:1983;469-483.
4. Buss J. L., Hasinoff B. B. The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes. Agents and Action. 40:1993;86-95.
5. Buss J. L., Hasinoff B. B. Ferrous ion strongly promotes the ring opening of the hydrolysis intermediates of the antioxidant cardioprotective agent dexrazoxane (ICRF-187). Archives of Biochemistry and Biophysics. 317:1995;121-127.
6. Burke T. G., Lee T. D., Van Balgooy J., Doroshow J. H. Characterization of the aqueous decomposition products of (+)1,2-bis(3,5-dioxopiperazinyl-1-yl)-propane (ICRF-187) by liquid chromatographic and mass spectral analysis. Journal of Pharmaceutical Sciences. 80:1991;338-340.
7. Cabantchik Z. I. Properties of permeation pathways induced in the human red cell membrane by malaria parasites. Blood Cells. 16:1990;421-432.
8. Clyde D. F. Recent trends in the epidemiology and control of malaria. Epidemiology Reviews. 9:1987;219-243.
9. Dawson K. M. Studies on the stability and cellular distribution of dioxopiperazines in cultured BHK-21S cells. Biochemical Pharmacology. 24:1975;2249-2253.
10. 14. Zeitschrift fur Parasitenkunde. 72:1986;709-713.
11. Glickstein H., Breuer B., Loyevsky M., Konijn A. M., Libman J., Shanzer A., Cabantchik Z. I. Differential cytotoxicity of iron chelators on malaria-infected cells versus mammalian cells. Blood. 87:1996;4871-4878.
12. Goodwin J. F., Whitten C. F. Chelation of ferrous sulfate solutions by desferrioxamine B. Nature. 205:1965;281-283.
13. Gordeuk V., Thuma P., Brittenham G., Mclaren C., Parry D., Backenstose A., Biemba G., Msiska R., Holmes L, Mckinley E., Vargas L., Gilkeson R., Poltera A. A. Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. New England Journal of Medicine. 327:1992;1474-1477.
14. Hasinoff B. B. The interaction of the cardioprotective agent ICRF-187 ((+) -1,2-bis(3,5-dioxopiperazinyl-1-yl)propane; its hydrolysis product (ICRF-198); and other chelating agents with the Fe (III) and Cu (II) complexes of adriamycin. Agents and Action. 26:1989;378-385.
15. Hasinoff B. B. The hydrolysis activation of the doxorubucin cardioprotective agent ICRF-187 ((+)-1,2-bis(3,%-dioxopiperazinyl-1-yl)propane). Drug Metabolism and Disposition. 18:1990;344-439.
16. Hasinoff B. B., Reinders F. X., Clark V. The enzymatic hydrolysis-activation of the adriamycin cardioprotective agent (+)-1,2-bis(3, 5-dioxopiperazinyl-1-yl)propane. Drug Metabolism and Disposition. 19:1991;74-80.
17. Hasinoff B. B., Venkataram S., Singh M., Kushak T. I. Metabolism of the cardioprotective agents dexrazoxane (ICRF-187) and levrazoxane (ICRF-186) by the isolated hepatocyte. Xenobiotica. 24:1994;977-987.
18. Huang Z.-X., May P. M., Quinlan K. M., Williams D. R., Creighton A. M. Metal binding by pharmaceuticals. Part 2. Interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumor agent ICRF-159 and its inactive homologue ICRF-192. Agents Actions. 12:1982;536-542.
19. Lambros C., Vanderberg J. P. Synchronization ofPlasmodium falciparum. Journal of Parasitology. 65:1979;418-420.
20. Loyevsky M., Cabantchik Z. I. Antimalarial action of hydrophilic drugs: Involvement of aqueous access routes to intracellular parasites. Molecular Pharmacology. 45:1994;446-452.
21. Lytton S. L., Loyevsky M., Mester B., Libman J., Landau I., Shanzer A., Cabantchik Z. I. In vivo antimalarial action of a lipophilic iron (III) chelator: Suppression ofPlasmodium vinckei. American Journal of Hematology. 43:1993;217-220.
22. Mellouk S., Berbiguier N., Druilhe P., Sedegah M., Galey B., Yuan L., Leef M., Charoenvit Y., Paul C., Hoffman S. Evaluation of anin vitro. World Health Organization. 68:1990;52-59.
23. Pollack S., Rossan R. N., Davidson D. E., Escajadillo A. Desferrioxamine suppressesPlasmodium falciparumaotus. Proceedings of the Society for Experimental Biology and Medicine. 184:1987;162-164.
24. Seifert C. F., Nesser M. E., Thompson D. F. Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Annals of Pharmacotherapy. 28:1994;1063-1071.
25. Sillen L. G., Martell A. E. "Stability Constants," Special Publ. No. 17. 1964;The Chemical Society, London.
26. Trager W., Jensen J. B. Continuous culture of human malaria parasites. Science. 193:1976;673-675.
27. 3+. Cancer Research. 50:1990;2307-2310.
28. Vogel C. L., Gorowski E., Davila E., Eisenberger M., Kosinski J., Agarwal R. P., Saravaj N. Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors. Investigational New Drugs. 5:1987;187-198.
29. World Health Organization 1974, Malaria Control in Countries Where Time-Limited Eradication Is Impracticable at Present, 537, WHO Technical Report Series.
30. Yayon A., Cabantchik Z. I., Ginsburg H. Identification of the acidic compartment ofPlasmodium falciparum. EMBO Journal. 3:1984;2695-2700.